Aktienanalyse zu Penumbra Inc (PEN)PENPenumbra Inc

Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Penumbra Inc is a good buy right now due to its current price of $324.39, which is approximately 13% below the average analyst price target of $374. Additionally, the company has shown strong revenue growth, with Q2 2026 revenue reported at $390 million, a 12.5% increase year-over-year, and a gross margin of 67.9%, which is an improvement from the previous year. However, the main risk is the recent earnings miss, with a reported EPS of $0.88 against an estimate of $1.15, representing a 23.48% surprise, which may affect investor sentiment in the short term.

5 analysts cover PEN: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 344.64.